CD274 and neoplasm: As a reference point to compare with TMB and TMM, we also estimated the AUROC of PD-L1 immunohistochemistry for IC2+ (i.e. taking as positive the staining of ≥5% immune cells in the tumor microenvironment) in this subset of patients.